AKESO Aktie

 

CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a......

A lung cancer drug developed by Akeso Inc. extended patients' lives by about four months in a late-stage trial in China, results that will likely raise expectations for a closely watched new class of treatments....

HONG KONG, May 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2 in......

Hang Seng Indexes Company announced today (22nd) the results of its quarterly review as of end-March. The Hang Seng China Enterprises Index (HSCEI) will add HANSOH PHARMA (03692.HK) and AKESO (09926.HK), and remove SUNNY OPTICAL (02382.HK) and HAIER SMARTHOME (06690.HK). The number of constituents will remain unchanged at 50. Al......

HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented as an oral presentation at the 2026......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

HONG KONG, April 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, has secured multiple authoritative updates and upgrades across first-line and later-line settings in the......

BofAS issued a report stating that Akeso (09926.HK)'s cadonilimab recorded MoM growth against seasonality. In February, Akeso's sample drug sales amounted to RMB71.3 million, representing a YoY increase of 319.6%. Among which, cadonilimab sales reached RMB44.3 million, up 249.5% YoY and 9.6% MoM, achieving positive sequential gr......

There was HKD3.7 billion, HKD595.5 million and HKD289.8 million Southbound Trading net inflow to TRACKER FUND (02800.HK), CNOOC (00883.HK) and YOFC (06869.HK).There was HKD596 million, HKD502.6 million and HKD23.5 million Southbound Trading net outflow from BABA-W (09988.HK), SMIC (00981.HK) and AKESO (09926.HK).For Southbound T......

HONG KONG, April 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line......

China's healthcare sector has been drawing offshore capital to Hong Kong-listed stocks as investors look for safe havens amid global volatility in commodities. The Hang Seng Healthcare Index, tracking some of China's most innovative pharmaceutical companies including Akeso and Innovent Biologics, has surged about 13 per cent since March 23, outpacing the benchmark Hang Seng Index's about 6 per cent gain over the same period. “Although the Middle East conflict has created a lot of uncertainty and......

HONG KONG, April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter......

HONG KONG, March 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business. Commercial Operations Enter a New Phase of Growth In 2025, Akeso achieved......

AKESO (09926.HK) announced its 2025 annual results, reporting revenue of RMB30.56 billion, an increase of 43.9% year-on-year. Gross profit reached RMB24.04 billion, up by 31%. The loss expanded from RMB5.15 billion in the previous year to RMB11.13 billion, primarily due to an increase of RMB2.56 billion in impairment losses on e......

HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1,......

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products......

HONG KONG, March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II study (COMPASSION-03/AK104-201) of cadonilimab as a monotherapy for patients with recurrent......